Alecensa
E821687
anaplastic lymphoma kinase inhibitor
pharmaceutical drug
protein kinase inhibitor
targeted cancer therapy
Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Alecensa canonical | 2 |
How this entity was disambiguated
This entity first appeared as the object of triple T9806872 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Alecensa Context triple: [Chugai Pharmaceutical, hasProduct, Alecensa]
-
A.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Alecensa Target entity description: Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
-
A.
Inflectra
Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
-
B.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
C.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
D.
Verzenio
Verzenio is a prescription cancer medication (abemaciclib) used primarily to treat certain types of hormone receptor–positive, HER2-negative breast cancer.
-
E.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
anaplastic lymphoma kinase inhibitor
ⓘ
pharmaceutical drug ⓘ protein kinase inhibitor ⓘ targeted cancer therapy ⓘ |
| approvedBy |
European Medicines Agency
ⓘ
Japanese Pharmaceuticals and Medical Devices Agency ⓘ U.S. Food and Drug Administration ⓘ
linked to:
Food and Drug Administration
|
| canCross | blood–brain barrier ⓘ |
| developedBy | Chugai Pharmaceutical ⓘ |
| dosageForm | capsule ⓘ |
| hasActiveIngredient | alectinib ⓘ |
| hasAdministrationSchedule | twice daily dosing ⓘ |
| hasAdverseEffect |
anemia
ⓘ
constipation ⓘ edema ⓘ fatigue ⓘ |
| hasATCCode | L01ED04 ⓘ |
| hasBlackBoxWarning | hepatotoxicity ⓘ |
| hasChemicalFormula | C30H34N4O2 ⓘ |
| hasClinicalTrial |
ALEX trial
ⓘ
J-ALEX trial ⓘ |
| hasDrugClass |
ALK inhibitor
ⓘ
tyrosine kinase inhibitor ⓘ |
| hasHalfLife | about 33 hours ⓘ |
| hasInternationalNonproprietaryName | alectinib ⓘ |
| hasMechanismOfAction |
inhibition of ALK phosphorylation
ⓘ
inhibition of downstream ALK signaling pathways ⓘ |
| hasTradeName | Alecensa ⓘ |
| hasWarning |
bradycardia
ⓘ
interstitial lung disease ⓘ myalgia ⓘ pneumonitis ⓘ |
| indicatedFor |
first-line treatment of ALK-positive metastatic NSCLC
ⓘ
treatment of ALK-positive metastatic NSCLC after crizotinib ⓘ |
| isPrescriptionDrug | true ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| marketedBy |
F. Hoffmann-La Roche
ⓘ
linked to:
Roche
Genentech ⓘ |
| metabolism | CYP3A4 ⓘ |
| pregnancyCategory | may cause fetal harm ⓘ |
| routeOfAdministration | oral ⓘ |
| targets |
ALK fusion proteins
ⓘ
anaplastic lymphoma kinase ⓘ |
| treats |
ALK-positive NSCLC with brain metastases
ⓘ
ALK-positive non-small cell lung cancer ⓘ metastatic ALK-positive non-small cell lung cancer ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Alecensa Description of subject: Alecensa is a targeted cancer therapy (alectinib) primarily used to treat ALK-positive non-small cell lung cancer.
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.